Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Cardiovascular Autonomic Function in T2D
NCT02973477Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Michigan. Primary endpoint: Changes in Measures of Heart Rate Variability (Frequency Domain) at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02973477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973477.